SLC5A2 and hydrops fetalis: The low prescription rates of SGLT2 inhibitors are in line with a previous study from the Swedish HF registry; whereas, only 5.5% of patients with concomitant diabetes mellitus were treated with a SGLT2 inhibitor from 2016 to 2018 [45].